
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc is experiencing a positive trend in retail sales, particularly in Europe, anticipated to increase both sequentially and year-over-year in the third and fourth quarters. The company's financial position has improved significantly, with expectations of nearly doubling free cash flow to an estimated $205 million by 2025, indicating strong operational performance. Additionally, the enhancement of the balance sheet and liquidity reflects a robust capacity for free cash flow conversion, further supporting a favorable outlook for the company's financial health.
Bears say
Diebold Nixdorf Inc faces significant financial risks that contribute to a negative outlook for its stock, primarily due to challenges in offsetting tariff-related costs amid a volatile trade environment. The company is also experiencing disruptions in product shipments and services linked to the COVID-19 pandemic, alongside uncertainty in upgrade and replacement activity within its critical Banking vertical, which impacts revenue predictability. Furthermore, currency exchange volatility, particularly related to the BRL, EUR, and GBP, alongside a low average daily trading volume, signifies potential liquidity issues that could adversely affect investor confidence.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares